EXPRESSION OF THE COMPLEMENT REGULATORY PROTEINS CD21, CD55 AND CD59 ON BURKITT-LYMPHOMA LINES - THEIR ROLE IN SENSITIVITY TO HUMAN SERUM-MEDIATED LYSIS

被引:37
|
作者
KURAYA, M
YEFENOF, E
KLEIN, G
KLEIN, E
机构
[1] KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN
[2] HEBREW UNIV JERUSALEM,SCH MED,LAUTENBERG CTR GEN TUMOR IMMUNOL,JERUSALEM,ISRAEL
[3] NAGOYA CITY UNIV,SCH MED,DEPT MOLEC BIOL,NAGOYA,AICHI 467,JAPAN
关键词
D O I
10.1002/eji.1830220729
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
On a panel of nine human B cell lines we showed that the expression of the complement regulatory factors complement receptor type 2 (CR2; CD21), decay-accelerating factor, (DAF; CD55) and homologous restriction factor (HRF20, CD59) is not correlated. All lines expressed DAF, six lines carried detectable amounts of CR2 and three carried HRF20. Upon incubation in human serum, under conditions which allowed the activation of complement through the alternative pathway, the CR2-carrying lines bound C3 fragments and two of them (Ramos and one of its two sublines) were damaged. These two lines had the lowest DAF expression, less than 50 % of the cells reacted with the IA10 monoclonal antibody. By modulating the expression of the complement regulatory molecules, the lytic sensitivity of the B cell lines could be altered. Blockade of DAF on the HRF20-, CR2+ lines with the specific monoclonal antibodies increased their sensitivity to lysis by human serum. With the DAF- and HRF20+ cells significant lytic effect was obtained only when they were pretreated with both of the specific antibodies. Interferon-gamma or tumor necrosis factor-alpha treatment elevated the amount of CR2 on the low-CR2 expressor line (Ramos/HR1K) which thereafter bound higher amounts of C3 fragments and was lysed when incubated in human serum. This line had relatively low DAF level and lacked HRF20. The cytokine treatment did not alter the expression of these molecules. The CR2+ Ramos and the CR2- Rael cells were treated with 5-azacytidine which induced HRF20 and increased DAF expression. In parallel with this change Ramos cells became resistant to C-mediated lysis. The experiments with the panel of human B cell lines showed thus that cytolysis through activation of complement in homologous serum can be regulated at several steps by cell surface molecules.While expression of CR2 was required for C3 fixation, DAF and HRF20 inhibited lysis. By independent modulation of the quantities of these molecules, cells acquired or lost their sensitivity.
引用
收藏
页码:1871 / 1876
页数:6
相关论文
共 50 条
  • [41] Altered Expression of Complement Regulatory Proteins CD35, CD46, CD55, and CD59 on Leukocyte Subsets in Individuals Suffering From Coronary Artery Disease
    Mishra, Nitesh
    Mohata, Madhav
    Narang, Rajeev
    Lakshmy, R.
    Hazarika, Anjali
    Pandey, R. M.
    Das, Nibhriti
    Luthra, Kalpana
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [42] Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    Golay, J
    Zaffaroni, L
    Vaccari, T
    Lazzari, M
    Borleri, GM
    Bernasconi, S
    Tedesco, F
    Rambaldi, A
    Introna, M
    [J]. BLOOD, 2000, 95 (12) : 3900 - 3908
  • [43] Mechanisms by which the surface expression of the glyeosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines
    Hatanaka, M
    Seya, T
    Matsumoto, M
    Hara, T
    Nonaka, M
    Inoue, N
    Takeda, J
    Shimizu, A
    [J]. BIOCHEMICAL JOURNAL, 1996, 314 : 969 - 976
  • [44] HUMAN CD46, CD55 AND CD59 EXPRESSION INFLUENCE ON SWINE TRANSGENIC FETAL FIBROBLASTS' SURVIVABILITY IN THE PRESENCE OF HUMAN COMPLEMENT COMPONENTS
    Zeyland, Joanna
    Lipinski, Daniel
    Slomski, Ryszard
    [J]. ANNALS OF ANIMAL SCIENCE, 2012, 12 (04): : 513 - 524
  • [45] Analysis of the level of mRNA expression of the membrane regulators of complement, Cd59, Cd55 and Cd46, in breast, cancer
    Rushmere, NK
    Knowlden, JM
    Gee, JMW
    Harper, ME
    Robertson, JF
    Morgan, BP
    Nicholson, RI
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (06) : 930 - 936
  • [46] Inhibition of mCRP (CD55, CD46 and CD59) expression by siRNA sensitizes tumor cells to complement attack
    Zell, S
    Geis, N
    Rutz, R
    Giese, T
    Schultz, S
    Kirschfink, M
    [J]. MOLECULAR IMMUNOLOGY, 2006, 43 (1-2) : 138 - 139
  • [47] Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas
    Ravindranath, Naren M. H.
    Shuler, Charles
    [J]. JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2006, 35 (09) : 560 - 567
  • [48] CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research
    Thielen, Astrid J. F.
    van Baarsen, Iris M.
    Jongsma, Marlieke L.
    Zeerleder, Sacha
    Spaapen, Robbert M.
    Wouters, Diana
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2018, 456 : 15 - 22
  • [49] Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
    Takei, K
    Yamazaki, T
    Sawada, U
    Ishizuka, H
    Aizawa, S
    [J]. LEUKEMIA RESEARCH, 2006, 30 (05) : 625 - 631
  • [50] THE EXPRESSION OF THE COMPLEMENT REGULATORS CD46, CD55, AND CD59 BY HUMAN SPERM DOES NOT PROTECT THEM FROM ANTISPERM ANTIBODY-MEDIATED AND COMPLEMENT-MEDIATED IMMUNE INJURY
    DCRUZ, OJ
    HAAS, GG
    [J]. FERTILITY AND STERILITY, 1993, 59 (04) : 876 - 884